Table 1.

Possibly related treatment-emergent adverse events (>10% all grades) for tumor-specific cohorts

TEAEGrade 1Grade 2Grade 3Grade 4All gradesa (N = 173)b
Diarrhea75 (43%)25 (15%)9 (5%)0109 (63%)
Nausea59 (34%)15 (9%)4 (2%)078 (45%)
Fatigue38 (22%)27 (16%)5 (3%)070 (41%)
Vomiting31 (18%)10 (6%)2 (1%)043 (25%)
Leukopenia9 (5%)17 (10%)17 (10%)043 (25%)
Thrombocytopenia21 (12%)7 (4%)12 (7%)040 (23%)
Neutropenia6 (4%)15 (9%)16 (9%)2 (1%)39 (23%)
Anemia13 (8%)14 (8%)7 (4%)034 (20%)
Anorexia22 (13%)8 (5%)0030 (17%)
Increased creatininec12 (7%)7 (4%)0019 (11%)
Weight loss14 (8%)4 (2%)0018 (10%)
  • NOTE: Data are represented as n (%).

  • aNo grade 5 events were reported.

  • bIncludes all tumor-specific cohorts receiving single-agent abemaciclib for NSCLC, glioblastoma, breast cancer, melanoma, or colorectal cancer.

  • cAbemaciclib inhibits renal transporters that mediate tubular secretion of creatinine, so serum creatinine may not accurately reflect renal function in patients receiving abemaciclib.